Green Journals

International Approved Journals

Journal Information

Journal Title	Future Oncology
Publisher	Taylor and Francis Ltd.
ISSN	1479-6694
E-ISSN	1744-8301
Database	SCOPUS
Domain	Health Sciences, Life Sciences

Classification History

Year	A+	A	B	C
2026		✓	✓	
2025		✓	✓	
2024		✓	✓	
2023		✓	✓	
2021/2022		✓	✓	
2020		✓	✓	
2019		✓	✓	
2018		✓		

Classification: The table above shows all journal classifications recorded for each classification year in the Green Journals database. A journal may have more than one classification in the same year.

Recent Articles

Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS
2026-11-6 Pages 1-14
Authors: Debu Tripathy, Joanne L. Blum, Meghan S. Karuturi et al.
DOI: 10.1080/14796694.2026.2747581

Efficacy and safety of Disitamab Vedotin (RC48-ADC) monotherapy versus combination therapy with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis
2026-11-6 Pages 1-12
Authors: Qing Liangliang, Li Lingyi, Li Xianyong et al.
DOI: 10.1080/14796694.2026.2757484

Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05
2026-11-6 Pages 1-10
Authors: Veronique Dieras, Giuseppe Curigliano, Miguel Martin et al.
DOI: 10.1080/14796694.2026.2753928

Zanidatamab in the treatment of esophagogastric adenocarcinoma
2026-11-6 Pages 1-11
Authors: Orla M. Fitzpatrick, Geoffrey Y. Ku
DOI: 10.1080/14796694.2026.2760738

Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial
2026-11-6 Pages 1-11
Authors: Dongsheng Yue, Federico Cappuzzo, Wenxiang Wang et al.
DOI: 10.1080/14796694.2026.2743385

PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC
2026-11-6 Pages 1-12
Authors: Mehmet Altan, Vishal Navani, Hye Ryun Kim et al.
DOI: 10.1080/14796694.2026.2752788

Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study
2026-11-4 Pages 1-18
Authors: Xiuning Le, Antonio Passaro, Yuanyuan Zhao et al.
DOI: 10.1080/14796694.2026.2749355

Treatment patterns and characteristics of Chinese patients with advanced or resectable melanoma: a multicenter retrospective study
2026-11-1 Pages 1-12
Authors: Yu Jiang, Junjie Gu, Yu Chen et al.
DOI: 10.1080/14796694.2026.2744073

Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor
2026-10-31 Pages 1-13
Authors: José Manuel Pérez-García, Antonio Llombart-Cussac, Elena López-Miranda et al.
DOI: 10.1080/14796694.2026.2753794

Falcon – multicancer early detection (MCED) real-world evidence (RWE) registry
2026-10-30 Pages 1-9
Authors: Ronan J. Kelly, Peter J. Hulick, Henry Mark Dunnenberger et al.
DOI: 10.1080/14796694.2026.2753325